loading
전일 마감가:
$3.24
열려 있는:
$3.2
하루 거래량:
331.94K
Relative Volume:
0.18
시가총액:
$3.15M
수익:
$12.99M
순이익/손실:
$-23.72M
주가수익비율:
-0.0327
EPS:
-97.2514
순현금흐름:
$-23.28M
1주 성능:
-37.37%
1개월 성능:
-41.67%
6개월 성능:
-96.86%
1년 성능:
-99.17%
1일 변동 폭
Value
$3.1004
$3.42
1주일 범위
Value
$3.1004
$5.0799
52주 변동 폭
Value
$2.81
$485.37

Aptevo Therapeutics Inc Stock (APVO) Company Profile

Name
명칭
Aptevo Therapeutics Inc
Name
전화
206-838-0500
Name
주소
2401 4TH AVE., SEATTLE, WA
Name
직원
37
Name
트위터
@aptevo
Name
다음 수익 날짜
2024-11-12
Name
최신 SEC 제출 서류
Name
APVO's Discussions on Twitter

APVO을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
APVO
Aptevo Therapeutics Inc
3.19 3.15M 12.99M -23.72M -23.28M -97.25
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
442.35 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
522.33 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
318.23 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
559.88 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
255.89 28.51B 3.81B -644.79M -669.77M -6.24

Aptevo Therapeutics Inc Stock (APVO) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2018-11-05 개시 Ladenburg Thalmann Buy
2017-10-05 재개 Piper Jaffray Overweight

Aptevo Therapeutics Inc 주식(APVO)의 최신 뉴스

pulisher
Jun 18, 2025

Top Small Cap Stocks Worth WatchingJune 18th - MarketBeat

Jun 18, 2025
pulisher
Jun 18, 2025

Crude Oil Moves Higher; US Weekly Jobless Claims Decline - Benzinga

Jun 18, 2025
pulisher
Jun 18, 2025

Aptevo Therapeutics raises $8 million in registered direct offering - Investing.com Australia

Jun 18, 2025
pulisher
Jun 18, 2025

Dow Surges 150 Points; Korn Ferry Earnings Top Views - Benzinga

Jun 18, 2025
pulisher
Jun 18, 2025

Aptevo Therapeutics (APVO) Secures $8M Through Direct Offering - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Aptevo Therapeutics announces $8M at-the-market equity offering with warrants; shares more than double - MSN

Jun 18, 2025
pulisher
Jun 18, 2025

Aptevo Therapeutics raises $8 million in registered direct offering By Investing.com - Investing.com India

Jun 18, 2025
pulisher
Jun 18, 2025

Why Is Micro-Cap Aptevo Stock Trading Higher On Wednesday?Aptevo Therapeutics (NASDAQ:APVO) - Benzinga

Jun 18, 2025
pulisher
Jun 18, 2025

Aptevo Therapeutics Announces $8 Million Offering Priced At-the-Market Under Nasdaq Rules | APVO Stock News - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

An early stage 85% remissions rate in AML drives Aptevo’s stock surge - BioWorld MedTech

Jun 18, 2025
pulisher
Jun 18, 2025

Aptevo Therapeutics Announces $8 Million Offering Priced At-the-Market Under Nasdaq Rules - ACCESS Newswire

Jun 18, 2025
pulisher
Jun 18, 2025

Aptevo Secures $8M Funding: Biotech Company Accelerates Cancer Drug Development Pipeline - Stock Titan

Jun 18, 2025
pulisher
Jun 18, 2025

Aptevo Therapeutics stock soars after impressive AML treatment results - Investing.com

Jun 18, 2025
pulisher
Jun 18, 2025

Aptevo Therapeutics stock soars after impressive AML treatment results By Investing.com - Investing.com Canada

Jun 18, 2025
pulisher
Jun 18, 2025

Why did Aptevo Therapeutics Shares Skyrocket in Premarket Trading Today? - Tokenist

Jun 18, 2025
pulisher
Jun 18, 2025

Aptevo Therapeutics Skyrockets on Game-Changing AML Drug News - RagingBull

Jun 18, 2025
pulisher
Jun 18, 2025

Aptevo reports 85% remission rate in frontline AML trial By Investing.com - Investing.com Nigeria

Jun 18, 2025
pulisher
Jun 18, 2025

Aptevo Therapeutics (APVO) Shows Promising Results in RAINIER Tr - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Aptevo Says Its Mipletamig Therapy Achieves 85% Remission Rate in Leukemia Patients; Shares Soar Pre-Bell - MarketScreener

Jun 18, 2025
pulisher
Jun 18, 2025

Aptevo Therapeutics (APVO) Shows Promising Results in AML Trial - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Aptevo Therapeutics announces new clinical data from RAINIER trial - TipRanks

Jun 18, 2025
pulisher
Jun 18, 2025

Aptevo announces clinical data from ongoing Phase 1b/2 RAINIER trial - TipRanks

Jun 18, 2025
pulisher
Jun 18, 2025

Breakthrough AML Drug Achieves 85% Remission Rate: New Hope for Previously Untreatable Patients - Stock Titan

Jun 18, 2025
pulisher
Jun 17, 2025

Aptevo Therapeutics Signs Equity Purchase Agreement - TipRanks

Jun 17, 2025
pulisher
Jun 16, 2025

APVO Secures Roth Capital Partners as Exclusive Placement Agent - GuruFocus

Jun 16, 2025
pulisher
Jun 15, 2025

Short Interest in Aptevo Therapeutics Inc. (NASDAQ:APVO) Decreases By 55.0% - Defense World

Jun 15, 2025
pulisher
Jun 14, 2025

Aptevo Stock Rises On $2.1M Registered Direct Offering, Warrant Sale: Retail Sentiment Touches Year-High - MSN

Jun 14, 2025
pulisher
Jun 13, 2025

Aptevo Participating in the BIO International Convention | APVO Stock News - GuruFocus

Jun 13, 2025
pulisher
Jun 13, 2025

Aptevo Sends Business Development Team to BIO 2025: Major Partnership Opportunities Ahead - Stock Titan

Jun 13, 2025
pulisher
May 29, 2025

Aptevo Therapeutics Inc. (NASDAQ:APVO) Sees Large Decrease in Short Interest - Defense World

May 29, 2025
pulisher
May 25, 2025

Aptevo Therapeutics (APVO) Trading Suspended as News Awaits | AP - GuruFocus

May 25, 2025
pulisher
May 23, 2025

Aptevo Therapeutics (APVO) Trading Suspended as News Awaits | APVO Stock News - GuruFocus

May 23, 2025
pulisher
May 23, 2025

Aptevo Therapeutics Approves 1-for-20 Reverse Stock Split - TipRanks

May 23, 2025
pulisher
May 22, 2025

Aptevo Therapeutics Announces Reverse Stock Split - TipRanks

May 22, 2025
pulisher
May 22, 2025

Aptevo Therapeutics to Implement 1-for-20 Reverse Stock Split - marketscreener.com

May 22, 2025
pulisher
May 22, 2025

Aptevo Therapeutics Announces 1-for-20 Reverse Stock Split as pa - GuruFocus

May 22, 2025
pulisher
May 22, 2025

Aptevo Therapeutics (APVO) Announces 1-for-20 Reverse Stock Split | APVO Stock News - GuruFocus

May 22, 2025
pulisher
May 22, 2025

Aptevo Therapeutics enacts reverse stock split to maintain Nasdaq compliance - Investing.com

May 22, 2025
pulisher
May 22, 2025

Aptevo Therapeutics Announces 1-for-20 Reverse Stock Split as part of Nasdaq Compliance Plan - ACCESS Newswire

May 22, 2025
pulisher
May 22, 2025

Aptevo's Dramatic 1:20 Reverse Split Cuts Shares from 13.5M to 0.7M in Nasdaq Compliance Push - Stock Titan

May 22, 2025
pulisher
May 18, 2025

StockNews.com Begins Coverage on Aptevo Therapeutics (NASDAQ:APVO) - Defense World

May 18, 2025
pulisher
May 16, 2025

Aptevo Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 16, 2025
pulisher
May 15, 2025

Aptevo reports high remission in AML patients with new drug By Investing.com - Investing.com South Africa

May 15, 2025
pulisher
May 15, 2025

APVO: Promising Trial Results Propel AML Treatment Innovations | - GuruFocus

May 15, 2025
pulisher
May 15, 2025

APVO: Promising Trial Results Propel AML Treatment Innovations | APVO Stock News - GuruFocus

May 15, 2025
pulisher
May 15, 2025

Aptevo reports high remission in AML patients with new drug - Investing.com Australia

May 15, 2025
pulisher
May 15, 2025

Aptevo Therapeutics Reports 1Q25 Financial Results And Provides an Update on Mipletamig | APVO Stock News - GuruFocus

May 15, 2025
pulisher
May 15, 2025

Aptevo Therapeutics Reports 1Q25 Financial Results And Provides an Update on Mipletamig - ACCESS Newswire

May 15, 2025
pulisher
May 14, 2025

Breakthrough: New AML Drug Shows 90% Remission Rate With Zero Cytokine Release Syndrome - Stock Titan

May 14, 2025
pulisher
May 12, 2025

Aptevo Therapeutics (APVO) Expected to Announce Earnings on Wednesday - Defense World

May 12, 2025
pulisher
May 10, 2025

Aptevo Therapeutics (NASDAQ:APVO) Now Covered by Analysts at StockNews.com - Defense World

May 10, 2025

Aptevo Therapeutics Inc (APVO) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$20.61
price up icon 0.78%
$36.03
price up icon 0.39%
$21.65
price up icon 1.34%
$105.24
price up icon 0.02%
$104.98
price up icon 0.19%
biotechnology ONC
$264.93
price down icon 1.26%
자본화:     |  볼륨(24시간):